Skip to main content
SpringerLink
Log in

Management of Acute Myocardial Infarction in the Elderly

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The prevalence of myocardial infarction (MI) is high among the elderly population. Many of the physiological and morphological changes attributable to “normal” aging predispose older adults to cardiovascular instability. The incidence of both MIs and their associated morbidity and mortality increase with aging. Older MI patients may therefore derive substantial benefit from appropriately selected therapeutic intervention. In fact, given the high morbidity and mortality associated with MI in the elderly, aggressive therapeutic strategies may be particularly warranted.

There are a number of age-related cardiovascular changes that contribute to the increasing incidence of MI as adults age. However, age itself is not a contraindication to aggressive therapy. Common MI management options include invasive and pharmaceutical strategies. The relative advantages of angioplasty and thrombolytics must be considered. Other drugs used in the treatment of MI include β-blockers, ACE inhibitors, nitrates, aspirin, anticoagulants, magnesium, antiarrhythmics and calcium antagonists. Significant peri-infarction complications, including heart failure, hypotension, arrhythmias, myocardial rupture and cardiogenic shock, often occur in older adults. Age-specific management strategies for these complications are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wei JY. Age and the cardiovascular system. N Engl J Med 1992; 327: 1735–9

    PubMed  CAS  Google Scholar 

  2. Forman DE, Bernai JLG, Wei JY. Management of acute myo-cardial infarction in the very elderly. Am J Med 1992; 93: 315–26

    PubMed  CAS  Google Scholar 

  3. Graves EJ. National hospital discharge survey: annual summary, 1990. Hyattsville, MD: National Center for Health Statistics, Public Health Service, Vital and Health Statistics, series 13, no. 112, 1992

    Google Scholar 

  4. Goldberg RJ, Gore JM, Gurwitz JH, et al. The impact of age on the incidence and prognosis of initial myocardial infarction: the Worcester Heart Attack Study. Am Heart J 1989; 117: 543–9

    PubMed  CAS  Google Scholar 

  5. Montague TJ, Ikuta RM, Wong RY, et al. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987–1989). Am J Cardiol 1991; 68: 855–7

    Google Scholar 

  6. Smith SC, Gilpin E, Ahnve S, et al. Outlook after acute myocardial infarction in the very elderly compared with that in patients aged 65 to 75 years. J Am Coll Cardiol 1990; 16: 784–92

    PubMed  Google Scholar 

  7. Rich MW. Acute myocardial infarction in the elderly. Cardio 1990; 7(10): 79–90

    Google Scholar 

  8. Kapantais G, Powell-Griner E. Characteristics of persons dying of disease of the heart: preliminary data for the 1986 National Mortality Followback Survey. Advance data from vital and health statistics: No. 172. Hyattsville, MD: National Center for Health Statistics, 1989

    Google Scholar 

  9. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol 1993; 23: 1273–7

    Google Scholar 

  10. Gurwitz JH, Osganian V, Goldberg RJ, et al. Diagnostic testing in acute myocardial infarction. Am J Epidemiol 1991; 134: 948–57

    PubMed  CAS  Google Scholar 

  11. Goldberg RJ, Gore JM, Gurwitz JH, et al. The impact of age on the incidence and prognosis of acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J 1989; 117: 543–9

    PubMed  CAS  Google Scholar 

  12. Latting CA, Silverman ME. Acute myocardial infarction in hospitalized patients over age 70. Am Heart J 1980; 100: 311–8

    PubMed  CAS  Google Scholar 

  13. Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med 1993; 329: 1442–8

    PubMed  CAS  Google Scholar 

  14. Rich MW, Bosner MS, Chung MK, et al. Is age an independent predictor of early and late mortality in patients with acute myocardial infarction?. Am J Med 1992; 92: 7–13

    PubMed  CAS  Google Scholar 

  15. Sagie A, Rotenberg Z, Weinberger I, et al. Acute myocardial infarction in elderly patients hospitalized in the coronary care unit versus the general medical ward. J Am Geriatr Soc 1987; 35: 915–9

    PubMed  CAS  Google Scholar 

  16. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991; 18: 657–62

    PubMed  CAS  Google Scholar 

  17. Waller BF, Roberts WC. Cardiovascular disease in the very elderly: analysis of 40 necropsy patients aged 90 years and older. Am J Cardio 1983; 51: 403–22

    CAS  Google Scholar 

  18. Yin FCP. The aging vasculature and its effects on the heart. In: Weisfeldt ML, editor. The aging heart: its function and response to stress. Vol 12. New York: Raven Press, 1980: 137–214

    Google Scholar 

  19. Hachamovitch R, Wicker P, Capasso JM, et al. Alterations of coronary blood flow and reserve with aging in Fischer 344 rats. Am J Physiol 1989; 256: H66–H73

    PubMed  CAS  Google Scholar 

  20. Olivetti G, Melissari M, Capasso JM, et al. Cardiomyopathy of the aging human heart. Circ Res 1991; 68: 1560–8

    PubMed  CAS  Google Scholar 

  21. Lakatta EG, Yin FCP. Myocardial aging: functional alterations and related cellular mechanisms. Am J Physiol 1982; 242: H927–41

    PubMed  CAS  Google Scholar 

  22. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986; 315: 417–23

    Google Scholar 

  23. Keen WD, Savage MP, Fischman DL, et al. Comparison of coronary angiographic findings during the first six hours of non-Q-wave and Q-wave myocardial infarction. Am J Cardiol 1994; 74: 324–8

    PubMed  CAS  Google Scholar 

  24. Berger CJ, Murabito JM, Evans JC, et al. Prognosis after first myocardial infarction: comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 1992; 268: 1545–51

    PubMed  CAS  Google Scholar 

  25. Krone RJ, Friedman E, Thanavaro S, et al. Long-term prognosis after first Q-wave (transmural) or non-Q-wave (nontransmu-ral) myocardial infarction: analysis of 593 patients. Am J Cardiol 1983; 52: 234–9

    PubMed  CAS  Google Scholar 

  26. Thanavaro S, Krone RJ, Kleiger RE, et al. Inhospital prognosis of patients with first nontransmural and transmural infarctions. Circulation 1980; 61: 29–33

    PubMed  CAS  Google Scholar 

  27. Chung MK, Bosner MS, McKenzie JP, et al. Prognosis of patients ≥70 years of age with non-Q-wave acute myocardial infarction compared with younger patients with similar in-farcts and with patients ≥70 years of age with Q-wave acute myocardial infarction. Am J Cardiol 1995; 75: 18–22

    PubMed  CAS  Google Scholar 

  28. Simari RD, Berger PB, Bell MR, et al. Coronary angioplasty in acute myocardial infarction: primary, immediate adjunctive, rescue, or deferred adjunctive approach?. Mayo Clin Proc 1994; 69: 346–58

    PubMed  CAS  Google Scholar 

  29. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673–9

    PubMed  CAS  Google Scholar 

  30. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates?: a quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995; 91: 476–85

    PubMed  CAS  Google Scholar 

  31. Stone GW, Grines CL, Vlietstra R, et al. Primary angioplasty is the preferred therapy for women and the elderly with acute myocardial infarction: results of the Primary Angioplasty in Myocardial Infarction (PAMI) trial [abstract]. J Am Coll Cardiol 1993; 21(2): 330A

    Google Scholar 

  32. Holland KJ, O’Neill WW, Bates ER, et al. Emergency percutaneous transluminal coronary angioplasty during acute myocardial infarction for patients more than 70 years of age. Am J Cardiol 1989; 63: 399–403

    PubMed  CAS  Google Scholar 

  33. Lee TC, Laramee LA, Rutherford BD, et al. Emergency percutaneous transluminal coronary angioplasty for acute myocardial infarction in patients 70 years of age or older. Am J Cardiol 1990; 66: 663–7

    PubMed  CAS  Google Scholar 

  34. Eckman MH, Wong JB, Salem DN, et al. Direct angioplasty for acute myocardial infarction: a review of outcomes in clinical subsets. Ann Intern Med 1992; 117: 667–76

    PubMed  CAS  Google Scholar 

  35. Hochman JS, Boland J, Sleeper L, et al. Should age alone exclude patients in cardiogenic shock from consideration of CABG/PTCA [abstract). Circulation 1994; 90(4 Pt 2): 1–109

    Google Scholar 

  36. Gunnar RM, Bourdillon PDV, Dixon DW, et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. Circulation 1990; 82: 664–707

    PubMed  CAS  Google Scholar 

  37. The TIMI-IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI-IIIB Trial. Circulation 1994; 89: 1545–56

    Google Scholar 

  38. Applegate WB, Graves S, Collins T, et al. Acute myocardial infarction in elderly patients. South Med J 1984; 77: 1127–9

    PubMed  CAS  Google Scholar 

  39. Steinberg JS, Hochman JS, Morgan CD, et al. Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-average ECG: results of a multicenter randomized trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. Circulation 1994; 90: 746–52

    PubMed  CAS  Google Scholar 

  40. AIMS Trial Study Group. Effect of intravenous APSAC on motality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; I: 545–9

    Google Scholar 

  41. Effectiveness of intravenous thromolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Lancet 1986; I: 397–402

    Google Scholar 

  42. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; II: 349–60

    Google Scholar 

  43. The ISAM Study Group. A prospective trial of Intravenous Streptokinase in Acute Myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314: 1465–71

    Google Scholar 

  44. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; II: 525–30

    Google Scholar 

  45. AIMS Trial Study Group. Long-term effects of intravenous an-istreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990; 335: 427–31

    Google Scholar 

  46. Gruppo Italiano Per Lo Studio Delia Streptochinasi Nell’Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987; II: 871–4

    Google Scholar 

  47. Wilcox RG, von der Lippe G, Olsson CG, et al. Effects of al-teplase in acute myocardial infarction: 6-month results from the ASSET Study. Lancet 1990; 335: 1175–8

    PubMed  CAS  Google Scholar 

  48. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327: 7–13

    PubMed  CAS  Google Scholar 

  49. Pashos CL, Normand SUT, Garfinkle JB, et al. Trends in the use of drug therapies in patients with myocardial infarction: 1988 to 1992. J Am Coll Cardiol 1994; 23: 1023–30

    PubMed  CAS  Google Scholar 

  50. Pfeffer MA, Moye LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA 1991; 266: 528–32

    PubMed  CAS  Google Scholar 

  51. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103–14

    PubMed  CAS  Google Scholar 

  52. Rosenthal GE, Fortinsky RH. Differences in the treatment of patients with acute myocardial infarction according to patient age. J Am Geriatr Soc 1994; 42: 826–32

    PubMed  CAS  Google Scholar 

  53. Krumholz HM, Friesinger GC, Cook EF, et al. Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction. J Am Geriatr Soc 1994; 42: 127–31

    PubMed  CAS  Google Scholar 

  54. Yarzebski J, Goldberg RJ, Gore JM, et al. Temporal trends and factors associated with extent of delay to hospital arrival in patients with acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J 1994; 128: 255–63

    PubMed  CAS  Google Scholar 

  55. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–22

    Google Scholar 

  56. Chaitman BR, Thompson B, Wittry WD, et al. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from Thrombolysis in Myocardial Infarction phase I, open label studies and the Thrombolysis in Myocardial Infarction phase II pilot study. J Am Coll Car-diol 1989; 14: 1159–65

    CAS  Google Scholar 

  57. Anderson JL, Karagounis L, Allan A, et al. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991; 68: 166–70

    PubMed  CAS  Google Scholar 

  58. Maggioni AP, Franzosi MG, Santoro E, et al. The risk of stroke in patients with acute myocardial infarction after thrombo-lytic and antithrombotic treatment. N Engl J Med 1992; 327: 1–6

    PubMed  CAS  Google Scholar 

  59. Selker HP, Beshansky JR, Schmid CH, et al. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic Predictive Instrument (TPI) project results. Circulation 1994; 90: 1657–61

    PubMed  CAS  Google Scholar 

  60. Gruppo Italiano Per Lo Studio Dello Sopravvivenza Nell’Infarto Miocardico (GISSI-2). A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336: 65–71

    Google Scholar 

  61. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–70

    Google Scholar 

  62. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615–22

    Google Scholar 

  63. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82

    Google Scholar 

  64. The International Study Group. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71–5

    Google Scholar 

  65. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433–7

    PubMed  CAS  Google Scholar 

  66. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. N Engl J Med 1985; 313: 1369–75

    PubMed  CAS  Google Scholar 

  67. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396–403

    PubMed  Google Scholar 

  68. Patrano C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94

    Google Scholar 

  69. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320–31

    Google Scholar 

  70. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30

    Google Scholar 

  71. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175–80

    PubMed  CAS  Google Scholar 

  72. Park KC, Forman DE, Wei JY. Utility of beta-blockade treatment for older postinfarction patients. J Am Geriatr Soc 1995; 43: 751–5

    PubMed  CAS  Google Scholar 

  73. Forman DE, Wei JY. Beta-blockers in older patients with myocardial infarction [abstract]. JAMA 1991; 266: 2222

    PubMed  CAS  Google Scholar 

  74. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; II: 823–7

    Google Scholar 

  75. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; II: 57–66

    Google Scholar 

  76. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomised placebo-controlled international trial. Eur Heart J 1985; 6: 199–226

    Google Scholar 

  77. Roberts R, Rogers WJ, Mueller HS, et al. Immediate vs deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83: 422–37

    PubMed  CAS  Google Scholar 

  78. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. N Engl J Med 1989; 320: 618–27

    Google Scholar 

  79. Rapaport E. Should β-blockers be given immediately and con-comitantly with thrombolytic therapy in acute myocardial infarction?. Circulation 1991; 83: 695–7

    PubMed  CAS  Google Scholar 

  80. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982; 247: 1707–14

    Google Scholar 

  81. Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-re-lated reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 1982; 66: 1179–84

    PubMed  CAS  Google Scholar 

  82. Pederson TR, for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian Multicenter Study on timolol after myocardial infarction. N Engl J Med 1985; 313: 1055–8

    Google Scholar 

  83. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–7

    Google Scholar 

  84. Swedburg K, Held P, Kjekshus J, et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative North Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–84

    Google Scholar 

  85. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22

    Google Scholar 

  86. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345: 669–85

    Google Scholar 

  87. Ambrosioi E, Borghi C, Magnani B. The effect of the angioten-sin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80–5

    Google Scholar 

  88. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8

    Google Scholar 

  89. Pfeffer MA, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77

    PubMed  CAS  Google Scholar 

  90. Stein B, Fuster V. Antithrombotic therapy in acute myocardial infarction: prevention of venous, left ventricular and coronary artery thromboembolism. Am J Cardiol 1989; 64: 33B–40B

    PubMed  CAS  Google Scholar 

  91. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343: 499–503

    Google Scholar 

  92. Vaitkus PT, Barnathen ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 1993; 22: 1004–9

    PubMed  CAS  Google Scholar 

  93. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147–52

    PubMed  CAS  Google Scholar 

  94. The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; II: 989–94

    Google Scholar 

  95. Yusuf S, Collins R, MacMahon S, et al. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1988; I: 1088–92

    Google Scholar 

  96. GISSI-3 Investigators. Six-month effects of early treatment with lisinopril and nitroglycerin withdrawn 6-weeks after myocardial infarction: the GISSI-3 results in elderly patients [abstract]. Circulation 1994; 90(4 Pt 2): 1–109

    Google Scholar 

  97. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187–92

    PubMed  CAS  Google Scholar 

  98. Skolnick AE, Frishman WH. Calcium channel blockers in myocardial infarction. Arch Intern Med 1989; 149: 1669–77

    PubMed  CAS  Google Scholar 

  99. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1296–8

    Google Scholar 

  100. Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med 1986; 315: 423–9

    PubMed  CAS  Google Scholar 

  101. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92

    Google Scholar 

  102. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after myocardial infarction (The Danish Verapamil Infarction Trial II — DAVIT II). Am J Cardiol 1990; 66: 779–85

    Google Scholar 

  103. Teo KK, Yusuf S, Collins R, et al. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. BMJ 1991; 303: 1499–1503

    PubMed  CAS  Google Scholar 

  104. Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553–8

    PubMed  CAS  Google Scholar 

  105. Shechter M, Hod H, Chouraqui P, et al. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75: 312–3

    Google Scholar 

  106. Hine LK, Laird N, Hewitt P, et al. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989; 149: 2694–8

    PubMed  CAS  Google Scholar 

  107. Rich MW. The geriatric patient in the coronary care unit. In: Rich MW, editor. Coronary care for the house officer. Baltimore: Williams & Wilkins, 1989: 202–8

    Google Scholar 

  108. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983; 309: 331–6

    Google Scholar 

  109. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiar-rhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993; 270: 1589–95

    PubMed  CAS  Google Scholar 

  110. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–8

    PubMed  CAS  Google Scholar 

  111. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227–33

    Google Scholar 

  112. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16: 1711–8

    PubMed  CAS  Google Scholar 

  113. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992; 20: 1056–62

    PubMed  CAS  Google Scholar 

  114. Bayer AJ, Chadha JS, Farag RR, et al. Changing presentation of myocardial infarction with increasing age. J Am Geriatr Soc 1986; 34: 263–6

    PubMed  CAS  Google Scholar 

  115. Luchi RJ, Taffet GE, Teasdale TE. Congestive heart failure in the elderly. J Am Geriatr Soc 1991; 39: 810–25

    PubMed  CAS  Google Scholar 

  116. Forman DE, Wei JY. Treatment of congestive heart failure in the elderly. In: Wei JY, Shehan M, editors. Harvard textbook of geriatrics. Oxford: Oxford University Press. In press

  117. Kyriakides ZS, Kelesides K, Melanidis J, et al. Systolic functional response of normal older and younger adult left ventricles to dobutamine. Am J Cardiol 1986; 58: 816–9

    PubMed  CAS  Google Scholar 

  118. Lakatta EG. Diminished beta-adrenergic modulation of cardiovascular function in advanced age. Cardiol Clin 1986; 4(2): 185–200

    PubMed  CAS  Google Scholar 

  119. Rich MW, Imburgia M. Inotröpic response to dobutamine in elderly patients with decompensated heart failure. Am J Cardiol 1990; 65: 519–21

    PubMed  CAS  Google Scholar 

  120. Silke B, Verma SP, Midtbo KA, et al. Comparative haemodyna-mic dose-response effects of dobutamine and amrinone in left ventricular failure complicating acute myocardial infarction. J Cardiovasc Pharmacol 1987; 9: 19–25

    PubMed  CAS  Google Scholar 

  121. Rich MW, Woods WL, Davila-Roman VG, et al. A randomized comparison of intravenous dobutamine vs. amrinone in elderly patients with decompensated heart failure. J Am Geriatr Soc 1995; 43: 271–4

    PubMed  CAS  Google Scholar 

  122. Gage J, Rutman H, Lucido D, et al. Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 1986; 74: 367–73

    PubMed  CAS  Google Scholar 

  123. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Fra-mingham Heart Study. JAMA 1994; 271: 840–4

    PubMed  CAS  Google Scholar 

  124. Pasternack RC, Braunwald E, Sobel BE. Acute myocardial infarction. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine, 4th ed. Philadelphia: W.B. Saunders Co., 1992: 1200–91

    Google Scholar 

  125. Laupacis A, Albers G, Dunn M, et al. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102 Suppl 4: 426S–433S

    PubMed  CAS  Google Scholar 

  126. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994; 343: 687–91

    Google Scholar 

  127. Rashid A, Shah IU, Haboubi NY, et al. An audit of cardiac pacing in the elderly: effect of myocardial infarction on outcome. J Am Geriatr Soc 1993; 41: 488–90

    PubMed  CAS  Google Scholar 

  128. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Guidelines for cardiopulmo-nary resuscitation and emergency cardiac care. JAMA 1992; 268: 2171–302

    Google Scholar 

  129. Nakano T, Konishi T, Takezawa H. Potential prevention of myocardial rupture resulting from acute myocardial infarction. Clin Cardiol 1985; 8: 199–204

    PubMed  CAS  Google Scholar 

  130. Labovitz AJ, Miller LW, Kennedy HL. Mechanical complications of acute myocardial infarction. Cardiovasc Rev Rep 1984; 5: 948–61

    Google Scholar 

  131. Rich MW. Mechanical complications. In: Rich MW, editor. Coronary care for the house officer. Baltimore: Williams & Wilkins, 1989: 135–41

    Google Scholar 

  132. Myers MG, Baigrie RS, Charlat ML, et al. Are routine non-invasive tests useful in prediction of outcome after myocardial infarction in elderly people?. Lancet 1993; 342: 1069–72

    PubMed  CAS  Google Scholar 

  133. Herlitz J, Samuelsson SO, Richter A, et al. Prediction of rupture in acute myocardial infarction. Clin Cardiol 1988; 11: 63–9

    PubMed  CAS  Google Scholar 

  134. Oliva PB, Hammil SC, Edwards WD. Cardiac rupture, a clinically predictable complication of acute myocardial infarction: report of 70 cases with clinicopathologic correlations. J Am Coll Cardiol 1993; 22: 720–6

    PubMed  CAS  Google Scholar 

  135. Harrison MR, MacPhail B, Gurley JC, et al. Usefulness of color Doppler flow imaging to distinguish ventricular septal defect from acute mitral regurgitation complicating acute myocardial infarction. Am J Cardiol 1989; 64: 697–701

    PubMed  CAS  Google Scholar 

  136. Smyllie JH, Sutherland GR, Geuskens R, et al. Doppler color flow mapping in the diagnosis of ventricular septal rupture and acute mitral regurgitation after myocardial infarction. J Am Coll Cardiol 1990; 15: 1449–55

    PubMed  CAS  Google Scholar 

  137. Blanche C, Khan SS, Chaux A, et al. Postinfarction ventricular septal defect in the elderly: analysis and results. Ann Thorac Surg 1994; 57: 1244–7

    PubMed  CAS  Google Scholar 

  138. Lemery R, Smith HC, Giuliani ER, et al. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol 1992; 70: 147–51

    PubMed  CAS  Google Scholar 

  139. Clements SD, Story WE, Hurst JW, et al. Ruptured papillary muscle, a complication of myocardial infarction: clinical presentation, diagnosis, and treatment. Clin Cardiol 1985; 8: 93–103

    PubMed  Google Scholar 

  140. Jones MT, Schofield PM, Dark JF, et al. Surgical repair of acquired ventricular septal defect: determinants of early and late outcome. Circulation 1990; 82 Suppl IV: IV243–IV247

    Google Scholar 

  141. Vlodaver Z, Coe JI, Edwards JE. True and false left ventricular aneurysms: propensity for the latter to rupture. Circulation 1975; 51: 567–72

    PubMed  CAS  Google Scholar 

  142. Shabbo FP, Dymond DS, Rees GM, et al. Surgical treatment of false aneurysm of the left ventricle after myocardial infarction. Thorax 1983; 38: 25–30

    PubMed  CAS  Google Scholar 

  143. Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med 1994; 330: 1724–30

    PubMed  CAS  Google Scholar 

  144. Leor J, Goldbourt U, Reicher-Reiss H, et al. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. Am J Med 1993; 94: 265–73

    PubMed  CAS  Google Scholar 

  145. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med 1991; 325: 1117–22

    PubMed  CAS  Google Scholar 

  146. Bengston JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the inter-ventional era. J Am Coll Cardiol 1992; 20: 1482–9

    Google Scholar 

  147. Hibbard MD, Holmes DR, Bailey KR, et al. Percutaneous trans-luminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol 1992; 19: 639–46

    PubMed  CAS  Google Scholar 

  148. Lee L, Erbel R, Brown TM, et al. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol 1991; 17: 599–603

    PubMed  CAS  Google Scholar 

  149. Moosvi AR, Khaja F, Villanueva L, et al. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 1992; 19: 907–14

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Geriatrics and Cardiology, Miriam Hospital, Brown University, Providence, Rhode Island, 02906, USA

    Daniel E. Forman

  2. Coronary Care Unit and Geriatric Cardiology Program, Jewish Hospital at Washington University Medical Center, St Louis, Missouri, USA

    Michael W. Rich

Authors
  1. Daniel E. Forman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael W. Rich
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forman, D.E., Rich, M.W. Management of Acute Myocardial Infarction in the Elderly. Drugs & Aging 8, 358–377 (1996). https://doi.org/10.2165/00002512-199608050-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199608050-00005

Keywords

Search

Navigation